Cytosorbents Corp (CTSO) - Dilution Analysis

10-Q filing | 62.7M shares outstanding

10-K filing | 62.2M shares outstanding

10-Q filing | 62.8M shares outstanding

10-Q filing | 62.6M shares outstanding

10-Q filing | 60.7M shares outstanding

10-K filing | 62.5M shares outstanding

10-Q filing | 54.5M shares outstanding

S-3/A filing: The filing is for a shelf registration allowing the company to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units.

10-Q filing | 54.3M shares outstanding

S-3 filing: CytoSorbents Corporation files an S-3 registration statement to offer up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time.

8-K filing: CytoSorbents Corporation entered into a Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. for up to $20 million, and issued warrants to purchase 1,645,569 shares of the Company's common stock.

10-Q filing | 54.3M shares outstanding

10-K filing | 54.3M shares outstanding

8-K filing: CytoSorbents Corporation announced the closing of its registered direct offering of 7,733,090 shares of common stock together with warrants to purchase up to 2,706,561 shares of common stock.

8-K filing: CytoSorbents Corporation entered into a securities purchase agreement for the sale of 7,733,090 shares of common stock and warrants to purchase up to 2,706,561 shares for an aggregate gross purchase price of $10,285,009.70, with the offering expected to close on December 12, 2023. ($10.29M proceeds)

10-Q filing | 44.4M shares outstanding

10-Q filing | 44.0M shares outstanding

10-Q filing | 43.7M shares outstanding

10-K filing | 43.6M shares outstanding

10-Q filing | 43.6M shares outstanding

10-Q filing | 43.6M shares outstanding

10-Q filing | 43.5M shares outstanding

10-K filing | 43.4M shares outstanding

10-Q filing | 43.4M shares outstanding

10-Q filing | 43.3M shares outstanding

S-3/A filing: The company is registering an indeterminate number of securities up to an aggregate offering price of $150,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issued upon conversion, exercise, redemption, repurchase or exchange of any securities registered hereunder, including any applicable anti-dilution provisions.

S-3 filing: The company is registering an indeterminate number of securities with a proposed aggregate offering price of $150,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issued upon conversion, exercise, redemption, repurchase or exchange of any securities registered hereunder.

10-Q filing | 43.3M shares outstanding

10-K filing | 43.2M shares outstanding

10-Q filing | 43.2M shares outstanding

10-Q filing | 32.6M shares outstanding

8-K filing: CytoSorbents Corporation completed an underwritten public offering, issuing and selling 6,052,631 shares of common stock for gross proceeds of approximately $57.5 million. ($57.5M proceeds)

8-K filing: CytoSorbents Corporation announced the pricing of its underwritten public offering of 5,263,158 shares of common stock at $9.50 per share, for gross proceeds of approximately $50.0 million. The underwriters have a 30-day option to purchase up to an additional 789,473 shares. ($50.0M proceeds)

10-Q filing | 36.2M shares outstanding

10-K filing | 35.1M shares outstanding